



# Characterization of the muscular and cardiac diseases of the DMSXL mouse model, a transgenic mouse model for Myotonic Dystrophy type 1

Caroline Le Guiner, T Larcher, A Lafoux, G Toumaniantz, S Webb, A Bourdon, T Girard, K Martinais, C Babarit, M Ledevin, et al.

## ► To cite this version:

Caroline Le Guiner, T Larcher, A Lafoux, G Toumaniantz, S Webb, et al.. Characterization of the muscular and cardiac diseases of the DMSXL mouse model, a transgenic mouse model for Myotonic Dystrophy type 1. American Society of Gene & Cell Therapy, May 2023, LOS ANGELES, United States. hal-04096181

**HAL Id: hal-04096181**

**<https://hal.inrae.fr/hal-04096181>**

Submitted on 12 May 2023

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.




Caroline LE GUINER<sup>1</sup>, T. LARCHER<sup>2</sup>, A. LAFOUX<sup>3</sup>, G. TOUMANIANTZ<sup>4</sup>, S. WEBB<sup>5</sup>, A. BOURDON<sup>1</sup>, T. GIRARD<sup>1</sup>, K. MARTINAIS<sup>1</sup>, C. BABARIT<sup>2</sup>, M. LEDEVIN<sup>2</sup>, C. HUCHET<sup>1,3</sup>, A. HIVONNAIT<sup>4</sup>, L. HESBERT<sup>6</sup>, C. JOUNIER<sup>6</sup>, D. AUGEREAU<sup>6</sup>, E. AUDRAN<sup>1,7</sup>, O. ADJALI<sup>1</sup>, G. GOURDON<sup>8</sup>, P. MOULLIER<sup>5</sup>, J. VOTTELER<sup>5</sup>, S. HAMMOND<sup>5</sup> and A. TRETIAKOVA<sup>5</sup>

<sup>1</sup>Nantes Université, CHU de Nantes, INSERM UMR 1089, TaRGeT Lab - Nantes, France / <sup>2</sup>APEX, INRAE, ONIRIS, PanTher - Nantes, France / <sup>3</sup>Therassay, Capacités SAS - Nantes, France / <sup>4</sup>Institut du Thorax, Nantes Université, CHU de Nantes, CNRS - Nantes, France / <sup>5</sup>Asklepios BioPharmaceutical, Inc. - Durham, NC, USA / <sup>6</sup>Centre de Boisbonne, ONIRIS - Nantes, France / <sup>7</sup>CBS, Capacités SAS - Nantes, France / <sup>8</sup>Sorbonne Université, INSERM, Centre de Recherche en Myologie - Paris, France


## Context of the study

Myotonic Dystrophy type 1 (DM1) is an autosomal dominant, progressive, and multi-systemic genetic disorder affecting at least 900,000 individuals worldwide. It is primarily characterized by myotonia, muscular weakness, and muscle atrophy. Other clinical manifestations include cardiac conduction defects, cardio-respiratory problems, cataracts, endocrine dysfunction and frequent neurological manifestations. The disease is caused by unnaturally expanded repeats of CTG trinucleotide in the 3'-untranslated region of the *DMPK* (dystrophia myotonica protein kinase) gene. In DM1 patients, the number of CTG repeats within the mutant *DMPK* allele ranges from 50 to 5000. The number of repeats roughly correlates with disease onset, severity and life expectancy (more repeats correlated with earlier onset, more severe symptoms and shorter lifespan). CTG-containing mutant DMPK transcripts are toxic. They aggregate as nuclear *foci* and impact the expression and function of RNA-binding proteins (such as MBNL1 and CELF1), resulting in spliceopathy of downstream effector genes, which accounts for much of the disease phenotype. Several therapeutic approaches either pharmacological or gene-therapy based, are under investigation to address this unmet medical need. One current limitation for the efficient evaluation and development of therapeutic products is the lack of DM1 animal models that ideally recapitulate the symptoms and the complex pathophysiology of this disease. Among available animal models, one of the most relevant remains the DMSXL mouse model, which carries a 45-kb human genomic fragment including the *DMPK* gene with more than 1200 CTG repeats. The human *DMPK* transgene is under the control of its own promoter and has been shown to have an almost ubiquitous expression. Initial characterization studies demonstrated that homozygous DMSXL mice display several manifestations of the human DM1 pathology, including growth retardation, muscle defects, cognitive impairments, nuclear *foci*, and splicing abnormalities. After establishing a colony in our own facility, our goal was to define in our hands the most relevant and sensitive readouts that characterize this animal model, especially for its muscular and cardiac diseases, in both genders.


### STUDY DESIGN



### CLINICAL FOLLOW-UP



### MUSCLE FUNCTION




Muscular strength was assessed using forelimb and four limbs **grip test** at 4 months of age. Force was measured over 5 successive trials with a short latency between each test. Results were expressed as the mean of 3 median values obtained during the 5 tests. Results showed that DMSXL males and females exhibited significant and similar decreases of absolute force developed by forelimbs and by four limbs. However, these differences were no longer significant after body mass normalization for the calculation of relative force. Muscle resistance was also evaluated at using **treadmill** at 4 months of age. The time and the total distance to exhaustion were determined. No significant difference were observed between WT and DMSXL mice (data not shown).


### CARDIAC FUNCTION

At 4 months of age, conventional measurement of the **electrocardiography (EKG)** parameters was performed on anesthetized animals. Classical intervals and segments (P wave, RR interval, PR interval, QT interval, QRS interval) were measured, and compared between the different experimental groups. After basal measurements, animals were submitted to challenge with Flecainide (20mg/kg) which acts as a pharmacological stressor of conduction disorders. As the data were similar for males and females, sex-group data were pooled to explore the effect of the genotype. No significant difference were observed between WT and DMSXL mice, whether before or after the Flecainide challenge (data not shown).

During the same anesthesia, before and after Flecainide challenge, **2D-echocardiography and pulsed Doppler** was also performed to look for possible structural remodeling (left ventricular thickness, diameter and end-diastolic volume), as well as systolic function (ejection and shortening fractions) and diastolic function (E/A ratio, isovolumetric relaxation time =IVRT, and deceleration time). Again, as the data were similar for males and females, sex-group data were pooled. No modification of the systolic and diastolic functions were observed, whatever the experimental group and condition. However, significant reduction of the left ventricle diameter and end-diastolic volume were observed in the DMSXL animals, suggesting initiation of a structural remodeling in these animals at 4 months old.




### mRNA EXPRESSION LEVELS




After sacrifice at 1 month or 4 months of age, relative quantification of human DMPK (hDMPK), murine DMPK (mDMPK) and murine CELF1 (mCEL1) mRNA levels were performed using **RTqPCR analysis**. Murine HPRT1 mRNA was used as endogenous control. As the data were similar for males and females, sex-group data were pooled. As expected, expression of hDMPK mRNA only in the DMSXL mice, at similar levels between the different muscles. mDMPK and mCEL1 mRNAs were detected in both genotypes, with slight (often non statistically significant) reduced expressions observed in the DMSXL animals. To be noticed, slight decreases of the expression of these 3 mRNA were observed with age, whatever the genotype, suggesting a global physiological regulation of these expressions.

### SPLICING DEFECTS



After sacrifice at 1 month or 4 months of age, the splicing profiles of different murine mRNA were analyzed using semi-quantitative **RT-PCR analysis**. As the data were similar for males and females, sex-group data were pooled. No splicing modifications were observed for splicing of Insulin Receptor (*INSR*) exon 11, nor for Titin (*TTN*) exon 313 (data not shown). On the contrary, LIM Domain Binding 3 (*LBD3*) exon 11, Integrin Subunit Alpha 6 (*IGTA6*) exon 27 and Sorbin and SH3 Domain Containing A (*SORBS1*) exon 27, and Muscleblind Like Splicing Regulator 1 (*MBNL1*) exon 7 showed clear mis-splicing in DMSXL muscles.


### hDMPK NUCLEAR FOCI & MBNL1 COLOCALIZATION



After sacrifice at 1 month or 4 months of age, we investigated the presence of ribonuclear inclusions of sense hDMPK mRNA carrying CTG expansions (thereafter designed as **nuclear foci**) in heart and biceps femoris muscles using using **fluorescence in situ hybridization (FISH)** with a (CAG), fluorescent probe. Comparing to WT tissues in which no specific signal was detected, DMSXL muscles showed some nuclear foci, ranging from 1 up to 7 foci per nucleus, occasionally forming large ones. The number of nuclei with nuclear foci were counted using an automatized method, and showed a decrease from 1 to 4 months of age, especially in biceps femoris. As the data were similar for males and females, sex-group data were pooled.


In DMSXL skeletal muscles and heart, **IHC** using an antibody specific for MBNL1 followed by the FISH technique showed **sequestration of the MBLN1 protein** next to the hDMPK nuclear foci.

### MUSCLE FIBER TYPES



After sacrifice at 1 month or 4 months of age, type of muscle fibers was determined based on their **expression of myosin heavy chain (MyHC, Ila and Iib) isoforms** in biceps femoris muscle. The percentage of each fiber type were compared between the experimental group. For all analyzed fiber types (i.e. type 1, 2A, X and 2B), no group effect was demonstrated and no difference in fiber type distribution could be identified (data not shown), maybe secondary to the high level of inter-individual variations.

### MUSCLE FIBER SIZE



## Conclusion

The data obtained in the frame of this study confirm that the DMSXL mouse model exhibits several features of the DM1 pathology at the muscular and cardiac levels. Expression of the mutated human DMPK messenger, which contained CUG-repeats, was detected in skeletal muscles and heart at both 1 and 4 months of age. This mutant transcript aggregates as foci in the nuclei of the muscle cells, where sequestration of the MBNL1 protein was also observed. As a consequence, and even if expression of the murine CELF1 mRNA was not modified, splicing defects of several downstream messengers was shown. Due to high level of inter-individual variations, no clear skeletal muscle histological abnormalities were observed. However, grip force was found reduced in 4 months old DMSXL animals. At the same age, the heart exhibited no EKG abnormalities, but an initiation of structural remodeling. Except for body weights, no gender effect was raised during this study. All these data will be of importance to design future preclinical studies for the evaluation of the efficacy and safety of different therapeutic products designed to treat DM1 at the muscular and cardiac levels, and using this unique DMSXL mouse model.

